2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 295

Efficacy and Safety of Fasinumab for Osteoarthritic Pain in Patients with Moderate to Severe Osteoarthritis of the Knees or Hips

Osteoarthritis – Clinical Aspects - Poster I

9:00AM-11:00AM: Abstract Number: 625

Efficacy and Safety of Intravenous Golimumab Plus Methotrexate in Patients 65 Years and Younger and Those Greater Than 65 Years of Age-a Post-Hoc Analysis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 733

Efficacy and Safety of Non-Biological Therapy (Non-Biological Drugs and Non-Pharmacological Interventions): A Systematic Literature Review for the 2016 Update of the ASAS/EULAR Recommendations for the Management of Axial Spondyloarthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 602

Efficacy and Safety of Switching Between Certolizumab Pegol and Adalimumab after Primary Anti-TNF Treatment Failure: 2-Year Results from a Randomized, Investigator-Blind, Superiority Head-to-Head Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 53

Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric Observational Study

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster I: Basic Science Focus

9:00AM-11:00AM: Abstract Number: 246

Efficacy of Colchicine and IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever: A Retrospective Analysis

Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

9:00AM-11:00AM: Abstract Number: 245

Efficacy of Cyclophosphamide Therapy in Idiopathic Retroperitoneal Fibrosis in a Retrospective Monocentric Analysis

Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

9:00AM-11:00AM: Abstract Number: 712

Efficacy of Golimumab for Nonradiographic Axial Spondyloarthritis (nr-axSpA): Subgroup Analysis By Baseline MRI and C-Reactive Protein Status

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 861

Efficacy of Methotrexate in Giant Cell Arteritis

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 49

Efficacy of Mirogabalin on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase 2 Proof-of-Concept Study

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster I: Basic Science Focus

9:00AM-11:00AM: Abstract Number: 848

Efficacy of Prucalopride in the Treatment of Systemic Sclerosis-Related Intestinal Involvement: Results from an Open Label Cross-over Study

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I

9:00AM-11:00AM: Abstract Number: 176

Endoplasmic Reticulum Stress Induces Lupus Kidney Disease By Facilitating Antigen Cross-Presentation Via the Increase of Endosomal Sec61

Innate Immunity and Rheumatic Disease - Poster I

9:00AM-11:00AM: Abstract Number: 64

Enrichment of Immune Pathways in Genes Under Geographically Restricted Adaptation in the Gullah African American Population of South Carolina

Genetics, Genomics and Proteomics - Poster I

9:00AM-11:00AM: Abstract Number: 399

Enthesitis in Juvenile Idiopathic Arthritis (JIA)

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis

9:00AM-11:00AM: Abstract Number: 243

Eosinophilic Angiocentric Fibrosis : A Mimic of Vasculitis in IgG4 Related Disease Spectrum

Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].